Impact of infliximab administration before plasma exchange therapy on patients with Kawasaki disease.

Abstract

Plasma exchange is a therapeutic option in refractory Kawasaki disease (KD). However, the effects of other immunosuppressive treatments on plasma exchange therapy have not been studied. We investigated the effect of infliximab on plasma exchange in KD as well as on the outcome in patients with KD. We studied 16 patients with intravenous immunoglobulin-resistant KD who finally underwent plasma exchange. The patients were divided into two groups: patients who received infliximab before plasma exchange (infliximab group) and patients who did not (non-infliximab group). The infliximab group showed a lesser median number of required total plasma exchange sessions (P = .002) and higher change and reduction rates in C-reactive protein before and after the first plasma exchange (both P = .027) than that of the non-infliximab group. Infliximab administered before plasma exchange reduced the number of total plasma exchange sessions and improved the plasma exchange efficacy.

• Authors: Shun Shimada, Daisuke Matsuoka, Tsubasa Murase, Akira Hachiya, Noriko Motoki, Yozo Nakazawa
• Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 24 Issue 6 Pg. 718-724 (Dec 2020) ISSN: 1744-9987 [Electronic] Australia
• PMID: 32077249 (Publication Type: Journal Article)
• Copyright: © 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Chemical References

• Immunoglobulins, Intravenous
• Immunologic Factors
• Immunosuppressive Agents
• Tumor Necrosis Factor Inhibitors
• C-Reactive Protein
• Infliximab

Topics

• C-Reactive Protein (analysis)
• Child, Preschool
• Female
• Humans
• Immunoglobulins, Intravenous (administration & dosage)
• Immunologic Factors (administration & dosage)
• Immunosuppressive Agents (administration & dosage)
• Infant
• Infliximab (administration & dosage)
• Japan (epidemiology)
• Male
• Mucocutaneous Lymph Node Syndrome (diagnosis, epidemiology, immunology, therapy)
• Plasma Exchange (methods)
• Retrospective Studies
• Treatment Outcome
• Tumor Necrosis Factor Inhibitors (administration & dosage)